Aggression by omission: Redefining and measuring an understudied construct.

Researchers of aggression have classically focused on what has been previously called active aggression-the deliberate infliction of harm through the direct application of deleterious consequences. However, the counterpart to this, what was originally called passive aggression, has gone understudied, and its definition has mutated beyond its original conceptualization. The present two studies (N's 196 and 220, respectively) attempted to examine passive aggression as originally defined-the deliberate withholding of behavior to ensure that a target is harmed-and renaming it aggression by omission (ABO), in contrast to aggression by commission (ABC).

"I Avenge; Others Aggress": A Victim-Perpetrator Asymmetry in Judging Whether a Transgression Was Motivated by Revenge.

In two studies, victims differed from perpetrators as to whether they viewed a transgression as motivated by a desire for revenge. When participants wrote about autobiographical episodes in which they hurt others, they were somewhat likely to report that they were motivated by revenge; when the same participants wrote about episodes in which others hurt them, they were less likely to report that the perpetrators were motivated by revenge. This asymmetry could act as a barrier to reconciliation.

An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Kinases play a critical role in cellular signaling and are dysregulated in a number of diseases, such as cancer, diabetes, and neurodegeneration. Therapeutics targeting kinases currently account for roughly 50% of cancer drug discovery efforts. The ability to explore human kinase biochemistry and biophysics in the laboratory is essential to designing selective inhibitors and studying drug resistance.

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Genomic studies have linked mTORC1 pathway-activating mutations with exceptional response to treatment with allosteric inhibitors of mTORC1 called rapalogs. Rapalogs are approved for selected cancer types, including kidney and breast cancers. Here, we used sequencing data from 22 human kidney cancer cases to identify the activating mechanisms conferred by mTOR mutations observed in human cancers and advance precision therapeutics.